Abstract
Intensity-modulated proton therapy minimizes the incidental irradiation of normal tissues in patients with head and neck cancer relative to intensity-modulated photon (x-ray) therapy and has been associated with lesser treatment-related toxicity and improved quality of life. A phase II/III randomized trial sponsored by the US National Cancer Institute is currently underway to compare deintensification treatment strategies with intensity-modulated proton therapy vs intensity-modulated photon (x-ray) therapy for patients with advanced-stage oropharyngeal tumors. After significant input from numerous stakeholders, the phase III portion of the randomized trial was redesigned as a noninferiority trial with progression-free survival as the primary endpoint. The process by which that redesign took place is described here.
Original language | English (US) |
---|---|
Pages (from-to) | 108-113 |
Number of pages | 6 |
Journal | Seminars in Radiation Oncology |
Volume | 28 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2018 |
All Science Journal Classification (ASJC) codes
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research